These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30745381)

  • 1. Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.
    Rees VE; Deveson Lucas DS; López-Causapé C; Huang Y; Kotsimbos T; Bulitta JB; Rees MC; Barugahare A; Peleg AY; Nation RL; Oliver A; Boyce JD; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation.
    Ciofu O; Riis B; Pressler T; Poulsen HE; Høiby N
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2276-82. PubMed ID: 15917521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Within-host whole genome analysis of an antibiotic resistant Pseudomonas aeruginosa strain sub-type in cystic fibrosis.
    Sherrard LJ; Tai AS; Wee BA; Ramsay KA; Kidd TJ; Ben Zakour NL; Whiley DM; Beatson SA; Bell SC
    PLoS One; 2017; 12(3):e0172179. PubMed ID: 28273168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucoidy, quorum sensing, mismatch repair and antibiotic resistance in Pseudomonas aeruginosa from cystic fibrosis chronic airways infections.
    Feliziani S; Luján AM; Moyano AJ; Sola C; Bocco JL; Montanaro P; Canigia LF; Argaraña CE; Smania AM
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
    Breen SKJ; Harper M; López-Causapé C; Rogers KE; Tait JR; Smallman TR; Lang Y; Lee WL; Zhou J; Zhang Y; Bulitta JB; Nation RL; Oliver A; Boyce JD; Landersdorfer CB
    Int J Antimicrob Agents; 2024 Jun; 63(6):107161. PubMed ID: 38561094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients.
    Colque CA; Albarracín Orio AG; Feliziani S; Marvig RL; Tobares AR; Johansen HK; Molin S; Smania AM
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071060
    [No Abstract]   [Full Text] [Related]  

  • 7. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
    Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections.
    Maciá MD; Blanquer D; Togores B; Sauleda J; Pérez JL; Oliver A
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3382-6. PubMed ID: 16048951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypermutability in environmental Pseudomonas aeruginosa and in populations causing pulmonary infection in individuals with cystic fibrosis.
    Kenna DT; Doherty CJ; Foweraker J; Macaskill L; Barcus VA; Govan JRW
    Microbiology (Reading); 2007 Jun; 153(Pt 6):1852-1859. PubMed ID: 17526842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole genome sequencing reveals the emergence of a Pseudomonas aeruginosa shared strain sub-lineage among patients treated within a single cystic fibrosis centre.
    Wee BA; Tai AS; Sherrard LJ; Ben Zakour NL; Hanks KR; Kidd TJ; Ramsay KA; Lamont I; Whiley DM; Bell SC; Beatson SA
    BMC Genomics; 2018 Aug; 19(1):644. PubMed ID: 30165811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.
    Oliver A; Cantón R; Campo P; Baquero F; Blázquez J
    Science; 2000 May; 288(5469):1251-4. PubMed ID: 10818002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypermutable Pseudomonas aeruginosa in Cystic fibrosis patients from two Brazilian cities.
    Lutz L; Leão RS; Ferreira AG; Pereira DC; Raupp C; Pitt T; Marques EA; Barth AL
    J Clin Microbiol; 2013 Mar; 51(3):927-30. PubMed ID: 23303495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of hypermutation and collateral sensitivity in antimicrobial resistance diversity of
    Vanderwoude J; Azimi S; Read TD; Diggle SP
    mBio; 2024 Feb; 15(2):e0310923. PubMed ID: 38171021
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants.
    Ciofu O; Mandsberg LF; Bjarnsholt T; Wassermann T; Høiby N
    Microbiology (Reading); 2010 Apr; 156(Pt 4):1108-1119. PubMed ID: 20019078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombination is a key driver of genomic and phenotypic diversity in a Pseudomonas aeruginosa population during cystic fibrosis infection.
    Darch SE; McNally A; Harrison F; Corander J; Barr HL; Paszkiewicz K; Holden S; Fogarty A; Crusz SA; Diggle SP
    Sci Rep; 2015 Jan; 5():7649. PubMed ID: 25578031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic and phenotypic relatedness of Pseudomonas aeruginosa isolates among the major cystic fibrosis patient cohort in Italy.
    Cigana C; Melotti P; Baldan R; Pedretti E; Pintani E; Iansa P; De Fino I; Favari F; Bergamini G; Tridello G; Cirillo DM; Assael BM; Bragonzi A
    BMC Microbiol; 2016 Jul; 16(1):142. PubMed ID: 27400750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic determinants of antimicrobial resistance in polymyxin B resistant Pseudomonas aeruginosa isolated from airways of patients with cystic fibrosis.
    Simão FA; Almeida MM; Rosa HS; Marques EA; Leão RS
    Braz J Microbiol; 2024 Jun; 55(2):1415-1425. PubMed ID: 38619733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudomonas aeruginosa syntrophy in chronically colonized airways of cystic fibrosis patients.
    Qin X; Zerr DM; McNutt MA; Berry JE; Burns JL; Kapur RP
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5971-81. PubMed ID: 22964251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas aeruginosa Isolates From a Cohort of Mexican Children With Cystic Fibrosis Show Adaptation to a Chronic Phenotype.
    Rosales-Reyes R; Rodríguez-Alvarado M; Lezana-Fernández JL; Sánchez-Lozano JY; Gayosso-Vázquez C; Jarillo-Quijada MD; Toledano-Tableros JE; Arredondo-Mercado MJ; Alcántar-Curiel MD; Lincopan N; Vidal JE; Lascurain R; Valvano MA; Santos-Preciado JI
    Pediatr Infect Dis J; 2020 Oct; 39(10):899-906. PubMed ID: 32453200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.